Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.47 |
| ▸ | AURKA | O14965 | 15/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15704911 | 0.91 | FLT3 (0.47) | FLT3AURKAAURKBIGF1R | |
| SCHEMBL15704863 | 0.88 | AURKA (0.53) | AURKAAURKB | |
| SCHEMBL16065636 | 0.88 | FLT3 (0.47) | FLT3AURKAAURKB | |
| SCHEMBL16065643 | 0.88 | EGFR (0.49) | FLT3AURKAAURKB | |
| SCHEMBL17175452 | 0.86 | AURKA (0.41) | AURKAAURKB | |
| SCHEMBL15704844 | 0.84 | AURKA (0.44) | AURKAAURKB | |
| SCHEMBL15704838 | 0.84 | AURKA (0.44) | AURKAAURKBIGF1R | |
| SCHEMBL17175711 | 0.84 | FLT3 (0.47) | FLT3AURKAAURKBIGF1R | |
| SCHEMBL15704876 | 0.84 | IGF1R (0.45) | FLT3AURKAAURKBIGF1R | |
| SCHEMBL15704846 | 0.84 | AURKA (0.45) | AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10245261-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | NANTBIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170189400-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9550760-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | NANTBIOSCIENCE, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9458137-B2 | Substituted indol-5-ol derivatives and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150291564-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. (US) | 2015-10-15 | — | — | US | disclosed |
| WO-2014145403-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189400-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | FLT3 723/4885AURKA 796/4885AURKB 406/4885 |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | GRK5, GRK3, MTMR1 | FLT3 708/4885AURKA 1063/4885AURKB 468/4885 |
| US-10245261-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | GRK5, GRK3, CDK5 | FLT3 723/4885AURKA 796/4885AURKB 406/4885 |
| US-20150291564-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | GRK5, GRK3, MTMR1 | FLT3 708/4885AURKA 1063/4885AURKB 468/4885 |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | FLT3 723/4885AURKA 796/4885AURKB 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.